Organigram Inc.
Canadian cannabis company
From Wikipedia, the free encyclopedia
Business
Organigram is a Canadian company that produces and sells cannabis and cannabis-derived products, including dried flower, pre-rolls, vapes, concentrates, oils, and edibles, for both the adult-use and medical markets.[5][6]
The company generates revenue through sales to provincial cannabis boards, direct sales to medical patients, and exports and partnerships in certain international markets.[6]
History
On March 24th, 2025, Organigram investors approved rebranding from Organigram Holdings to Organigram Global.[7][8]
In 2023, the company reported a quarterly profit of $5.3 million, reversing a $1.3 million loss a year earlier, as revenue rose to $43.3 million from $30.4 million and margins improved.[4]
In November 2025, the company announced that James Yamanaka, a former executive at British American Tobacco, was being appointed CEO effective around January 15, 2026, and that he would also join the company’s board.[9]
.svg){kind=small}
